Antiviral immune responses modulate the nature of central nervous system (CNS) disease in a murine model of multiple sclerosis

Immunological Reviews

Volumn 159, Issue , 1997, Pages 177-193

  Drescher, Kristen M ^a   Pease, Larry R ^a   Rodriguez, Moses ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; CYTOKINE; IMMUNOGLOBULIN; MYELIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEMYELINATING DISEASE; DEMYELINATION; DISEASE RESISTANCE; GENETIC MANIPULATION; H2 SYSTEM; IMMUNE RESPONSE; IMMUNOPATHOLOGY; MACROPHAGE; MOUSE; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCID MOUSE; VIRUS IMMUNITY; VIRUS PATHOGENESIS; VIRUS RESISTANCE; VIRUS VIRULENCE;

EID: 0030700427     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb01015.x     Document Type: Review

References (107)

1. Mendez MF, Pogacar S. Malignant monophasic multiple sclerosis or "Marburg's disease". Neurology 1988;38:1153-1155.
2. Johnson MD, Lavin P, Whetsell WO. Fulminant monophasic multiple sclerosis. Marburg's type. J Neurol Neurosurg Psychiatry 1990;53: 918-921.
3. Gilbert JJ, Sadler M. Unsuspected multiple sclerosis. Arch Neurol 1983;40:533-536.
4. Kurtzke JF, Hyllested K. Multiple sclerosis in the Faroe Islands. I. Clinical and epidemiological features. Ann Neurol 1979;5:6-21.
5. Kurtzke JF, Hyllested K. Multiple sclerosis in the Faroe Islands. II. Clinical update, transmission, and the nature of MS. Neurology 1986;36:307-328.
6. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;i:1313-1315.
7. IFN-β MS Study Group. Interferon-1β is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
8. Lipton HL. Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect Immun 1975;11:1147-1155.
9. Dal Canto MC, Lipton HL. Ultrastructural immunohistochemical localization of virus in acute and chronic demyelinating Theiler's virus infection. Am J Pathol 1982;106:20-29.
10. Dal Canto MC, Lipton HL. Primary demyelination in Theiler's virus infection. An ultrastructural study. Lab Invest 1975;33:626-637.
11. Rodriguez M, Leibowitz JL, Lampert PW Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis. Ann Neurol 1983;13:426-433.
12. Aubert C, Chamorro M, Brahic M. Identification of Theiler's virus infected cells in the central nervous system of the mouse during demyelinating disease. Microb Pathog 1987;3:319-326.
13. Clatch RJ, Miller SD, Metzner R, Dal Canto MC, Lipton HL. Monocytes/macrophages isolated from the mouse central nervous system contain infectious Theiler's murine encephalomyelitis virus (TMEV). Virology 1990;176:244-254.
14. Rodriguez M, Leibowitz JL, Powell HC, Lampert PW. Neonatal infection with the Daniels strain of Theiler's murine encephalomyelitis virus. Lab Invest 1983;49:672-679.
15. Rodriguez M, Pavelko KD, Njenga MK, Logan WC, Wettstein PJ. The balance between persistent virus infection and immune cells determines demyelination. J Immunol 1996;157:5699-5709.
16. Lin X, Thiemann R, Pease LR, Rodriguez M. VP1 and VP2 capsid proteins of Theiler's virus are targets of H-2D-restricted cytotoxic lymphocytes in the central nervous system of B10 mice. Virology 1995;214:91-99.
17. Lin X, Pease LR, Rodriguez M. Differential generation of Class I H-2D-versus H-2K-restricted cytotoxicity against a demyelinating virus following central nervous system infection. Eur J Immunol 1997;27:963-970.
18. Lorch Y, Freidmann A, Lipton HL, Kotler M. Theiler's murine encephalomyelitis virus group includes two distinct genetic subgroups that differ pathologically and biologically. J Virol 1981;40:560-567.
19. Daniels JB, Pappenheimer AM, Richardson S. Observations on encephalomyelitis of mice (DA strain). J Exp Med 1952;96:517-530.
20. Lipton HL, Dal Canto MC. The TO strains of Theiler's viruses cause 'slow-virus like' infection in mice. Ann Neurol 1979;6:25-28.
21. Pevear DC, Borkowski J, Calendoff M, Oh CK, Ostrowski B, Lipton HL. Insights into Theiler's virus neurovirulence based on genomic comparison of the neurovirulent GDVII and less virulent BeAn strains. Virology 1988;165:1-12.
22. Pevear DC, Calendoff M, Rozhon E, Lipton HL. Analysis of the complete nucleotide sequences of the picornavirus Theiler's murine encephalomyelitis virus indicates that it is closely related to cardioviruses. J Virol 1987;61:1507-1516.
23. Chen HH, Kong WP, Zhang L, Ward PL, Roos RP. A picornaviral protein synthesized out of frame with the polyprotein plays a key role in a virus-induced immune-mediated demyelinating disease. Nat Med 1995;1:927-931.
24. Fu J, et al. Neurovirulence determinants of genetically engineered Theiler viruses. Proc Natl Acad Sci USA 1990;87:4125-4129.
25. Rodriguez M, Roos RP. Pathogenesis of early and late disease in mice infected with - Theiler's virus, using intratypic recombinant GDVII/DA viruses. J Virol 1992;66:217-225.
26. Zhang L, Senkowski A, Shim B, Roos RP. Chimeric cDNA studies of Theiler's murine encephalomyelitis virus neurovirulence. J Virol 1993;67:4404-4408.
27. Sato S, et al. A neutralization site of DA strain of Theiler's murine encephalomyelitis virus important for disease phenotype. Virology 1996;226:327-337.
28. Jarousse N, Martinat C, Syan S, Brahic M, McAllister A. Role of VP2 amino acid 141 in tropism of Theiler's virus within the central nervous system. J Virol 1996;70:8213-8217.
29. Lipton HL. Persistent Theiler's murine encephalomyelitis virus infection in mice depends on plaque size. J Gen Virol 1980;46:169-177.
30. Bureau JF, Montagutelli X, Bihl F, Lefebvre S, Guenet JL, Brahic M. Mapping loci influencing the persistence of Theiler's virus in the murine central nervous system. Nat Genet 1993;5:87-91.
31. Rodriguez M, Leibowitz J, David CS. Susceptibility to Theiler's Virus-Induced demyelination: mapping of the gene within the H-2D region. J Exp Med 1986;163:620-631.
32. Rodriguez M, David CS, Pease LR. The contribution of MHC gene products to demyelination by Theiler's virus. In: David CS, ed. H-2 antigens. New York: Plenum Publishing Corp. 1987. p. 747-756.
33. Bureau JF, Montagutelli X, Lefebvre S, Guenet JL, Pla M, Brahic M. The interaction of two groups of murine genes determines the persistence of Theiler's virus in the central nervous system. J Virol 1992;66:4698-4704.
34. b gene become resistant to persistent infection by Theiler's virus. J Virol 1994;68:4049-4052.
35. Melvold RW, Jokinen DM, Miller SD, Dal Canto MC, Lipton HL. Identification of a locus on mouse chromosome 3 involved in differential susceptibility to Theiler's murine encephalomyelitis virus-induced demyelinating disease. J Virol 1990;64:686-690.
36. Rodriguez M, David CS. Demyelination induced by Theiler's virus: influence of the H-2 haplotype. J Immunol 1985;135:2145-2148.
37. Patick AK, Pease LR, David CS, Rodriguez M. Major histocompatibility complex-conferred resistance to Theiler's virus-induced demyelinating disease is inherited as a dominant trait in B10 congenic mice. J Virol 1990;64:5570-5576.
38. Clatch RJ, Melvold RW, Miller SD, Lipton HL. Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease in mice is influenced by the H-2D region: correlation with TMEV-specific delayed-type hypersensitivity. J Immunol 1985;135:1408-1414.
39. Clatch RJ, Melvold RW, Dal Canto MC, Miller SD, Lipton HL. The Theiler's murine encephalomyelitis virus (TMEV) model for multiple sclerosis shows a strong influence of the murine equivalents of HLA-A, B, and C. J Neuroimmunol 1987;15:121-135.
40. dml mice. Ann Neurol 1993;33:208-212.
41. d transgene suppresses Theiler's virus-induced demyelination in susceptible strains of mice. J Neurovirol 1995;1:111-117.
42. Melvold RW, Jokinen DM, Knobler RL, Lipton HL. Variations in genetic control of susceptibility to Theiler's murine encephalomyelitis virus (TMEV) - induced demyelinating disease. I. Differences between susceptible SJL/J and resistant BALB/c strains map near the T cell beta-chain constant gene on chromosome 6. J Immunol 1987;138:1429-1433.
43. Rodriguez M, Patick AK, Pease LR, David CS. Role of T cell receptor V beta genes in Theiler's virus-induced demyelination of mice. J Immunol 1992;148:921-927.
44. Rodriguez M, Nabozny GH, Thiemann RL, David CS. Influence of deletion of T cell receptor Vβ genes on the Theiler's virus model of multiple sclerosis. Autoimmunity 1994;19:221-230.
45. Pease LR, Horton RM, Pullen JK, Cai Z. Structure and diversity of class I antigen presenting molecules in the mouse. Crit Rev Immunol 1991;11:1-32.
46. Pullen JK, Horton RM, Cai Z, Pease LR. Structural diversity of the classical H-2 genes: K, D, and L. J Immunol 1992;148:953-967.
47. Lindsley MD, Patick AK, Prayoonwiwat N, Rodriguez M. Coexpression of class I major histocompatibility antigen and viral RNA in central nervous system of mice infected with Theiler's virus: a model for multiple sclerosis. Mayo Clin Proc 1992;67:829-838.
48. Altintas A, Cai Z, Pease LR, Rodriguez M. Differential expression of H-2K and H-2D in the central nervous system of mice infected with Theiler's virus. J Immunol 1993;151:2803-2812.
49. Njenga MK, Pease LR, Wettstein PJ, Mak T, Rodriguez M. Interferon α/β mediates early virus-induced H-2D and H-2K expression in the central nervous system. Lab Invest 1997;77:71-84.
50. Lavi E, Suzumura A, Murasko DM, Murray EM, Silbergerg DH, Weiss SR. Tumor necrosis factor induces expression of Class I antigens on mouse astrocytes. J Neuroimmunol 1988;18:245-253.
51. Wong GHW, Bartlett PF, Clark-Lews I, Battye F, Schrader JW. Inducible expression of H-2 and Ia antigen on brain cells. Nature 1984;310:688-691.
52. Berzofsky J, Berkower I. Immunogenicity and antigen structure. In: Paul WE, ed. Fundamental Immunology. New York: Raven Press Ltd. 1992. p. 169-208.
53. Brodsky FM, Guagliardi LE. The cell biology of antigen processing and presentation. Annu Rev Immunol 1991;9:707-744.
54. Schmid DS, Rouse BT. The role of T cell immunity in control of herpes simplex virus. In: Rouse BT, ed. Herpes simplex virus. New York: Springer-Verlag; 1992. p. 57-74.
55. Zinkernagel RM, Althage A. Antiviral protection by virus-immune cytotoxic T cells: infected target cells are lysed before infectious virus progeny is assembled. J Exp Med 1977;145:644-651.
56. Ruby J, Ramshaw I. The antiviral activity of immune CD8+ T cells is dependent on interferon-gamma. Lymphokine Cytokine Res 1991;10: 353-358.
57. b molecules complexed with a viral VP2 peptide lacking a consensus anchor residue. J Virol 1997;71:5244-5250.
58. Dethlefs S, Escriou N, Brahic M, van der Werf S, Larsson-Sciard EL. Theiler's virus and mengo virus induce cross-reactive cytotoxic T lymphocytes restricted to the same immunodominant VP2 epitope in C57BL/6 mice. J Virol 1997;71:5361-5365.
59. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK recognition. Immunol Today 1991;11:237-242.
60. Paya CV, Patick A, Leibson PJ, Rodriguez M. Role of natural killer cells as immune effectors in encephalitis and demyelination induced by Theiler's virus. J Immunol 1989;143:95-102.
61. Paya CV, Kenmotsu N, Schoon RA, Leibson PJ. Tumor necrosis factor and lymphotoxin secretion by human natural killer cells leads to antiviral cytotoxicity. J Immunol 1988;141:1989-1995.
62. Laichalk LL, Danforth JM, Standiford TJ. Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol Med Microbiol 1996;15: 181-187.
63. Szalay G, Ladel CH, Blum C, Kaufmann SH. IL-4 neutralization or TNF-alpha treatment ameliorate disease by an intracellular pathogen in IFN-gamma receptor-deficient mice. J Immunol 1996;157:4746-4750.
64. Rodriguez M, Pavelko KD, Coffman RL. Gamma Interferon is critical for resistance to Theiler's virus-induced demyelination. J Virol 1995;69:7286-7290.
65. Fiette L, et al. Theiler's virus infection of 129 Sv mice that lack the interferon α/β or interferon γ receptors. J Exp Med 1995;181:2069-2076.
66. Issacs A, Lindemann J. Virus interference. I. The interferons. Proc R Soc Lond B 1957;147:258-267.
67. Hassel BA, Zhou A, Sotomayar C, Maran A, Silverman RH. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects to interferon. EMBO J 1993;12:3297-3304.
68. Chebath J, Benech P, Revel M, Vigneron M. Constitutive expression of (2′-5′) oligo A synthetase confers resistance to picornavirus infection. Nature 1987;330:587-588.
69. Mihara M, Ikuta M, Koishihara Y, Ohsugi Y. Interleukin 6 inhibits delayed-type hypersensitivity and the development of adjuvant arthritis. Eur J Immunol 1993;21:2327-2331.
70. Rodriguez M, Pavelko KD, McKinney CW, Leibowitz JL. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol 1994;153:3811-3821.
71. Aderka D, Le JM, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, Up37 cells, and in mice. J Immunol 1989;143:3517-3523.
72. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83:113-118.
73. Paya CV, Leibson PJ, Patick AK, Rodriguez M. Inhibition of Theiler's virus-induced demyelination in vivo by tumor necrosis factor alpha. Int Immunol 1990;2:909-913.
74. Larsson-Sciard EL, Dethlefs S, Brahic M. In vivo administration of interleukin-2 protects susceptible mice from Theiler's virus persistence. J Virol 1997;71:797-799.
75. Kimball ES. Experimental modulation of IL-1 production and cell surface molecule expression by levamisole. Ann N Y Acad Sci 1993;685:259-268.
76. Pullen LC, Park SH, Miller SD, Dal Canto MC, Kim BS. Treatment with bacterial LPS renders genetically resistant C57BL/6 mice susceptible to Theiler's virus-induced demyelinating disease. J Immunol 1995;155:4497-4503.
77. Olsson JE, Nilsson K. Gamma globulins of CSF and serum in multiple sclerosis: isoelectric focusing on polyacrylamide gel and agar gel electrophoresis. Neurology 1979;29:1381-1391.
78. Roos RP, Nalefski EA, Nitayaphan S, Variakojis R, Singh KK. An isoelectric focusing overlay study of the humoral immune response to Theiler's virus demyelinating disease. J Neuroimmunol 1987;13:305-314.
79. Rodriguez M, Lucchinetti CF, Clark RJ, Yaksh TL, Markowitz H, Lennon VA. Immunoglobulins and complement in demyelination induced in mice by Theiler's virus. J Immunol 1988;140:800-806.
80. Rodriguez M, Kenny JJ, Thiemann RL, Woloschak GE. Theiler's virus-induced demyelination in mice immunosuppressed with anti-IgM and in mice expressing the xid gene. Microb Pathog 1990;8:23-35.
81. Levy M, Aubert C, Brahic M. Theiler's virus replication in brain macrophages cultured in vitro. J Virol 1992;66:3188-3193.
82. Lipton HL, Dal Canto MC. Theiler's virus-induced demyelination: prevention by immunosuppression. Science 1976;192:62-64.
83. Lipton HL, Dal Canto MC. Contrasting effects of immunosuppression on Theiler's virus infection in mice. Infect Immun 1977;15:903-909.
84. Rodriguez M, Lafuse W, Leibowitz J, David CS. Partial suppression of Theiler's virus-induced demyelination in vivo by administration of monoclonal antibodies to immune response gene products (Ia antigens). Neurology 1986;36:964-970.
85. Rodriguez M, Quddus J. Effect of cyclosporin A, silica quartz dust and protease inhibitors on virus-induced demyelination. J Neuroimmunol 1986;13:159-174.
86. Rodriguez M, Siegel LM, Hovanec-Burns D, Bologa L, Graves MC. Theiler's virus-associated antigens on the surfaces of cultured glial cells. Virology 1988;166:463-474.
87. Rodriguez M. Virus-induced demyelination in mice: "dying back" of oligodendrocytes. Mayo Clin Proc 1985;60:433-436.
88. Roos RP, Wollmann R. DA strain of Theiler's murine encephalomyelitis virus induces demyelination in nude mice. Ann Neurol 1984;15:494-499.
89. Rosenthal A, Fujinami RS, Lampert PW. Mechanism of Theiler's virus-induced demylination in nude mice. Lab Invest 1986;54:515-522.
90. Welsh CJR, Tonks P, Nash AA, Blakemore WF. The effect of L3T4 T cell depletion on the pathogenesis of Theiler's murine encephalomyelitis virus infection in CBA mice. J Gen Virol 1987;68:1659-1667.
91. Rodriguez M, Sriram S. Successful therapy of TMEV-induced demyelination (DA strain) with monoclonal anti lyt2.2 antibody. J Immunol 1988;140:2950-2955.
92. Roos RP, Firestone S, Wollman R, Variakojis D, Arnason BGW. The effect of short term and chronic immunosuppression on Theiler's virus demyelination. J Neuroimmunol 1982;2:223-234.
93. Barbano RL, Dal Canto MC. Serum and cells from Theiler's virus-infected mice fail to injure myelinating cultures or to produce in vivo transfer of disease. The pathogenesis of Theiler's virus-induced demyelination appears to differ from that of EAE. J Neurol Sci 1984;66:283-293.
94. Miller SD, et al. Epitope spreading leads to myelin-specific autoimmune responses in SJL mice chronically infected with Theiler's virus. J Neurovirol 1997;3:S62-S65.
95. Qi Y, Dal Canto MC. Effect of Theiler's murine encephalomyelitis virus and cytokines on cultured oligodendrocytes and astrocytes. J Neurosci Res 1996;45:364-374.
96. Rodriguez M, Prayoonwiwat N, Howe C, Sanborn K. Proteolipid protein gene expression in demyelination and remyelination of the central nervous system: a model for multiple sclerosis. J Neuropathol Exp Neurol 1994;53:136-143.
97. Ozden S, Aubert C, Bureau JF, Gonzalez-Dunia D, Brahic M. Analysis of proteolipid protein and Po transcripts in mice infected with Theiler's virus. Microb Pathog 1993;14:123-131.
98. Fiette L, Aubert C, Brahic M, Rossi CP. Theiler's virus infection of beta 2-microglobulin-deficient mice. J Virol 1993;67:589-592.
99. Fiette L, Brahic M, Pena-Rossi C. Infection of class-II deficient mice by the DA strain of Theiler's virus. J Virol 1996;70:4811-4815.
100. b mice deficient in β2-microglobulin. J Immunol 1993;151:266-276.
101. Njenga MK, et al..Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice. J Virol 1996;70:1729-1737.
102. Gerety SJ, Rundell MK, Dal Canto MC, Miller SD. Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus-induced demyelinating disease. VI. Potentiation of demyelination with and characterization of an immunopathologic CD4+ T cell line specific for an immunodominant VP2 epitope. J Immunol 1994;152:919-929.
103. Lindsay MD, Rodriguez M. Characterization of the inflammatory response in the central nervous system of mice susceptible or resistant to demyelination by Theiler's virus. J Immunol 1989;142:2677-2682.
104. Pullen LC, Miller SD, Dal Canto MC, Kim BS. Class I-deficient resistant mice intracerebrally inoculated with Theiler's virus show an increased T cell response to viral antigens and susceptibility to demyelination. Eur J Immunol 1993;23:2287-2293.
105. Rodriguez M, Rivera-Quinones C, MurrayPD, Njenga MK, Wettstein PJ, Mak T. The role of CD4+ and CD8+ T cells in demyelinating disease following Theiler's virus infection: a model for multiple sclerosis. J Neurovirol 1997;3:S43-S45.
106. Lipton HL, Twaddle G, Jelachich ML. The predominant virus antigen burden is present in macrophages in Theiler's murine encephalomyelitis virus-induced demyelinating disease. J Virol 1995;69:2525-2533.
107. Rossi CP, et al. Role of macrophages during Theiler's virus infection. J Virol 1997;71:3336-3340.